TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS (TRICERATOPS)

A Randomized Placebo-Controlled TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS- The TRICERATOPS Study

A Randomized Placebo-Controlled TRIal of PPF3 vs. PlaCEbo in the TReatment of children and AdolescenTs with NeurOdeveloPmental DisorderS

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Ontario
      • Hamilton, Ontario, Canada, L8L 0A4
        • Not yet recruiting
        • McMaster University
        • Contact:
        • Principal Investigator:
          • Elisabetta Trinari, MD
      • Kingston, Ontario, Canada, K7L 3N6
        • Not yet recruiting
        • Queen's University
        • Contact:
        • Principal Investigator:
          • Marc Woodbury-Smith, MD
      • London, Ontario, Canada, N6A 5W9
        • Not yet recruiting
        • London Health Sciences Centre
        • Principal Investigator:
          • Janys Lim, MD
        • Contact:
      • Toronto, Ontario, Canada, M4G 1R8
        • Recruiting
        • Holland Bloorview Kids Rehabilitation Hospital
        • Principal Investigator:
          • Evdokia Anagnostou, MD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Outpatients 8-17 years of age, inclusive, with a weight ≥ 30 kg.

  • Already have participated in POND cohort

  • Females of childbearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.

  • Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria (American Psychiatric Association, 2013) for ASD. Diagnosis will be supported by the ADOS-2. Diagnostic and Statistical Manual (DSM-5) criteria will be established by a clinician with expertise with individuals with ASD.

  • Have a Clinical Global Impression-Severity (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill)

  • If already receiving interventions, must meet the following criteria:

  • If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening (6 weeks for Fluoxetine) and will not electively modify ongoing medications for the study duration.

    b. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions.

  • Have a negative pregnancy test at screening for patients who have experienced menarche

  • Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Qualified Investigator.

Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian.

Exclusion Criteria:

Please contact the site for details

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm 1

PPF3

Investigational

Placebo Comparator: Arm 2

Placebo

Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Adverse event
Time Frame: From enrollment to the end of week 16
From enrollment to the end of week 16
Clinical Global Impression Scale
Time Frame: From Screening to Week 16
From Screening to Week 16

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Evdokia Anagnostou, MD, Holland Bloorview Kids Rehabilitation Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

October 15, 2026

First Submitted That Met QC Criteria

October 21, 2026

First Posted (Actual)

October 26, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe